These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 9682370)

  • 1. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.
    Heath DG; Anderson GW; Mauro JM; Welkos SL; Andrews GP; Adamovicz J; Friedlander AM
    Vaccine; 1998 Jul; 16(11-12):1131-7. PubMed ID: 9682370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
    Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
    Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
    Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
    Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
    Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.
    Goodin JL; Nellis DF; Powell BS; Vyas VV; Enama JT; Wang LC; Clark PK; Giardina SL; Adamovicz JJ; Michiel DF
    Protein Expr Purif; 2007 May; 53(1):63-79. PubMed ID: 17293124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.
    Anderson GW; Heath DG; Bolt CR; Welkos SL; Friedlander AM
    Am J Trop Med Hyg; 1998 Jun; 58(6):793-9. PubMed ID: 9660466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice.
    Alvarez ML; Pinyerd HL; Crisantes JD; Rigano MM; Pinkhasov J; Walmsley AM; Mason HS; Cardineau GA
    Vaccine; 2006 Mar; 24(14):2477-90. PubMed ID: 16442673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
    Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the
    Biryukov S; Dankmeyer JL; Shamsuddin Z; Velez I; Rill NO; Rosario-Acevedo R; Klimko CP; Shoe JL; Hunter M; Ward MD; Cazares LH; Fetterer DP; Bozue JA; Worsham PL; Cote CK; Amemiya K
    Front Immunol; 2021; 12():726416. PubMed ID: 34512658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of bubonic and pneumonic plague using plant-derived vaccines.
    Alvarez ML; Cardineau GA
    Biotechnol Adv; 2010; 28(1):184-96. PubMed ID: 19931370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice.
    Little SF; Webster WM; Wilhelm H; Fisher D; Norris SL; Powell BS; Enama J; Adamovicz JJ
    Vaccine; 2010 Jan; 28(4):934-9. PubMed ID: 19925906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
    Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V
    Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague.
    Goodin JL; Powell BS; Enama JT; Raab RW; McKown RL; Coffman GL; Andrews GP
    Protein Expr Purif; 2011 Mar; 76(1):136-44. PubMed ID: 21055471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vaccination against plague using Yersinia pseudotuberculosis.
    Demeure CE; Derbise A; Carniel E
    Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
    Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
    Yang X; Hinnebusch BJ; Trunkle T; Bosio CM; Suo Z; Tighe M; Harmsen A; Becker T; Crist K; Walters N; Avci R; Pascual DW
    J Immunol; 2007 Jan; 178(2):1059-67. PubMed ID: 17202369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.